Renaissance Technologies’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-11,102
Closed -$56K 4105
2024
Q1
$56K Sell
11,102
-372
-3% -$2.31K ﹤0.01% 3469
2023
Q4
$77K Buy
+11,474
New +$101K ﹤0.01% 3369
2023
Q3
Sell
-2,390
Closed -$50K 4236
2023
Q2
$50K Sell
2,390
-13,199
-85% -$407K ﹤0.01% 3618
2023
Q1
$419K Buy
15,589
+5,346
+52% +$249K ﹤0.01% 2971
2022
Q4
$363K Buy
+10,243
New +$1.23M ﹤0.01% 3133
2021
Q4
Sell
-4,429
Closed -$888K 4309
2021
Q3
$888K Buy
4,429
+3,308
+295% +$786K ﹤0.01% 2613
2021
Q2
$286K Sell
1,121
-2,442
-69% -$609K ﹤0.01% 3161
2021
Q1
$946K Buy
+3,563
New +$1.12M ﹤0.01% 2634
2020
Q2
Sell
-9,039
Closed -$1.84M 3840
2020
Q1
$1.84M Buy
9,039
+4,268
+89% +$1.36M ﹤0.01% 2092
2019
Q4
$2.13M Sell
4,771
-1,940
-29% -$689K ﹤0.01% 2295
2019
Q3
$2.06M Sell
6,711
-3,243
-33% -$1.05M ﹤0.01% 2266
2019
Q2
$3.17M Buy
9,954
+656
+7% +$227K ﹤0.01% 2093
2019
Q1
$3.9M Buy
9,298
+860
+10% +$345K ﹤0.01% 1965
2018
Q4
$2.57M Sell
8,438
-856
-9% -$277K ﹤0.01% 2092
2018
Q3
$3.35M Buy
9,294
+1,620
+21% +$554K ﹤0.01% 2030
2018
Q2
$2.81M Buy
7,674
+2,206
+40% +$786K ﹤0.01% 2099
2018
Q1
$1.62M Buy
5,468
+2,234
+69% +$660K ﹤0.01% 2445
2017
Q4
$1.35M Buy
3,234
+600
+23% +$214K ﹤0.01% 2539
2017
Q3
$869K Buy
2,634
+1,853
+237% +$505K ﹤0.01% 2619
2017
Q2
$185K Buy
+781
New +$177K ﹤0.01% 3007
2015
Q2
Sell
-663
Closed -$5.65M 3427
2015
Q1
$5.65M Buy
663
+615
+1,281% +$5.38M 0.01% 1282
2014
Q4
$422K Buy
+48
New +$279K ﹤0.01% 2484

Other funds holding EIGR

Renaissance Technologies's EIGR Position: Q2 2024 in Review

Renaissance Technologies sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 11,102 shares — an estimated $56K sold.

Renaissance Technologies first reported a position in EIGR in Q4 2014 and held it in 22 quarters. The position peaked at $5.65M in Q1 2015. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Renaissance Technologies reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 11,102 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $56K.
  • Renaissance Technologies first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Renaissance Technologies's Eiger BioPharmaceuticals, Inc. position peaked at $5.65M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.